Support from readers like you keeps The Journal open.
You are visiting us because we have something you value. Independent, unbiased news that tells the truth. Advertising revenue goes some way to support our mission, but this year it has not been enough.
If you've seen value in our reporting, please contribute what you can, so we can continue to produce accurate and meaningful journalism. For everyone who needs it.
THE CEO OF Pfizer has said that there is “encouraging” data on whether the Pfizer BioNTech vaccine stops transmission.
Dr Albert Bourla said at the EPP Group health event that “more concrete data” would be available by February.
Studies to date have shown that its vaccine is highly effective at preventing a person who gets SARS-CoV-2 from becoming seriously ill with Covid-19, but separate research needs to be carried out as to its effectiveness at preventing transmission itself.
“Right now we want to see to the vaccine, in addition to protecting people, is also preventing transferring the virus,” Dr Bourla said.
“This is not conclusive yet. We know that in animals, [there is] significant protection from transferring the virus…. We haven’t [proven that in] humans yet.”
Advertisement
When asked how long the vaccine would give immunity to Covid-19 for, Bourla said that people who have been vaccinated for 6-7 months “are maintaining a very high level of protection”.
Dr Bourla also told the EPP Group event that it looks like there is a “very, very high efficacy” of the Pfizer-BioNTech vaccine against the two variants that appear to be able to transmit easier than other variants.
Studies have suggested that two variants – one found in the UK and another in South Africa – could be between 50-75% more transmissible.
Dr Bourla said that after a number of in vitro experiments, it appears that it will have a very high efficacy against these variants.
On the safety of the vaccine for children, he said that the Pfizer-BioNTech vaccine has been licenced for people aged 16 years old and above.
Pfizer are running clinical trials to examine the safety of the vaccine among children aged from 12-16, and Dr Bourla expects them to conclude in a few months, “maybe the first quarter”.
He said that any bottlenecks that there are currently in the production of the vaccine are a result of the vaccine not having been made before, coupled with the vaccines being needed in “extraordinary quantities”.
Related Reads
One million vaccinated by June 'not a bad estimation', says head of task force
79-year-old Dublin woman first in Republic of Ireland to get Covid-19 vaccine
Q&A: Answers to reader questions about the Covid-19 vaccine and Ireland's rollout plans
“We feel confident that we will dramatically increase the production of our vaccines.”
Right now, we expect this year to deliver 2 billion doses against the 1.3 billion [previously planned for this year]. And the efforts [to increase production] are not stopping.
When asked if the contract for vaccines with the European Union would be published, Dr Bourla said that they would look at publishing a version of the deal that keeps some information confidential “because I think it’s become quite sensitive” to make some of the information public.
Franz-Werner Haas, CEO of CureVac which is also developing a Covid-19 vaccine, said that the importance of a Europe-wide and global approach to battling the Covid-19 pandemic is that the virus doesn’t recognise borders, nationality, or the colour of skin.
The CureVac vaccine is in the third testing phase; if it cannot apply for authorisation by this Spring, it aims to produce the BioNTech vaccine.
Readers like you are keeping these stories free for everyone...
A mix of advertising and supporting contributions helps keep paywalls away from valuable information like this article.
Over 5,000 readers like you have already stepped up and support us with a monthly payment or a once-off donation.
To embed this post, copy the code below on your site
Close
40 Comments
This is YOUR comments community. Stay civil, stay constructive, stay on topic.
Please familiarise yourself with our comments policy
here
before taking part.
@Craic-Hommy: hopefully the government will get its finger out and vaccinate before the vaccines go off. I know for a fact that hospitals and nursing homes here are still trying to source fridges to store them. They have only just started looking for them and there is currently a shortage of pharmaceutical fridges in Europe as they were bought by other countries in advance of the vaccine rollout
@Critical Thinker: Do you have a source for any on that ? You do get that nursing home don’t need to have the type of refrigeration needed to store vaccines, yea ? They are nursing homes, not vaccine storage warehouses. Given some of your posts over the past few days, you saying “I know for a fact” doesn’t exactly fill me with confidence that what you are claiming is actually factual.
@Tommy Roche: exactly once defrosted Pfizer’s vaccine is good at fridge temp for 5 days, Moderna’s for 30 days. Seems strange a nursing home wouldn’t already have pharmaceutical fridges, or at the very least a regular fridge designated for pharmaceuticals
@NotMyIreland: it’s not standard cold storage, the Pfizer one needs to be store at – 70oC. A standard fridge runs between 1 and 5oC, a freezer is – 18oC.
Based on reports, Pfizer have said they will provide equipment to store Vaccines at the right temp. Would assume that’s in Regional hubs rather than every nursing home and hospital. 5 days should be plenty of time to get from Regional hubs into ppls arms locally
@NotMyIreland: seems strange to you. That means theres two possibilities. Every retirement home everywhere in the country is completely wrong. Or you dont know. It only seems strange because you dont know what you’re talking about but unfortunately people these days dont recognise a lack of their own knowledge and come out with statements like “seems strange that…”. Assume that people in a field, a field that you presumably are not in, know better.
@Tommy Roche: I wouldn’t take anyone’s word either, unless they have a PHD in the said subject and we all know that no-one knows much about Covid as it’s a relatively new virus. It will take virologists at least 10 yrs to study rolling data and understand Covid.
Also all data (Quantitive & Qualitative ) is bias anyway simply because individuals reporting symptoms or side effects process these in different ways.
Can anyone tell me when theh should start to see results in Israel as they are way ahead of everyone else? They have nearly a quarter of their population done. Tje way they’re going they’ll be done by early to mid february.
@Vonvonic: in the past week, transmission has gone from 7600 to 3600. Deaths from 25 to 2. Though there’s no way of knowing if it’s the vaccination or any other measures. The UK doesn’t seem to be yielding results
@TonyC – *Ventilation Is Key*: you can’t say it beginning to work if they are in lockdown as that’s meant to be reducing spread.
So you’d need data with no Lockdown.
@sean Coady: I am generally pro vaccine but we are told this went through rigorous testing yet they can’t even say if it prevents transmission of the virus.
@john doe: normally the vaccines are tested for safety and efficacy first and not transmission. Whats the point of testing for transmission if lots of ppl have side effects (safety) or vaccine doesn’t work (efficacy). The transmission required the test to be carried out for a longer duration i.e. about 1 yr. Hence the normal vaccine to market timeline is 4-5 yrs not 6-10 months. Here we are seeing a very small timeline hence only safety and efficacy was targeted.
Also its the main reason that none of the vaccines have full approval. Its only emergency use which means some data is still being generated.
@Jason Walsh: all along I’ve been very factual on this whole thing. Avoiding the hyperbole you always get on these boards. Dealing with what we know. But personally I think going by what we know, the vaccines we have available and what is coming down the line. And the new tests in trials that may give accurate results in less than 30 mins. I’d be confident that we’ll be done with any major restrictions by the end of the year. Some counties might require vaccine certs to enter, and perhaps some countries that still have significant levels of infection might limit large gatherings but I’d be surprised if there are any of the current restrictions that we have here still in place. The only way would be if the vaccines fail. In which case we’d be well and truly fooked. But I’m hopeful.
The people in the White House during the siege who got covid had all had the first round of vaccinations and were wearing masks. According to CNN, they reckon they caught it from their republican colleagues who had also had the first round of vaccines but we’re not wearing masks. The article didn’t clarify, though, if the republican colleagues had also tested positive. Anyway, if the CNN article is true, it shows us that one round only does not prevent transmission even when other measures are in place. Their symptoms were possibly mitigated.
2. It takes 4 weeks after the first Pfizer/BioTech vaccine dose to reach maximum immunity, that is 1 week after the 2nd dose (given 3 weeks later). Since the first doses were given on Monday Dec 14, just over 4 weeks ago, there are only a small number of people who have reached optimal immunity so far.
@David Jordan: what the optimal immunity figure yet is very unclear.
Would be good to get data after the second dose and not data from Lockdown reduction as it’s not going show up as much.
Assuming Protection and celebration for a vaccine that’s no real world efficiency seems like it should at least tell us sooner rather than later hopefully the data.
Anyone with prior infection can’t be counted as vaccine immune either.
So the vaccine doesn’t prevent Covid-19 but prevents the person who gets Covid from having symptoms and they are saying they’re not sure if it prevents transmission? Surely this is worse? Someone could have Covid, not know they have it cause they’ve been vaccinated and then spread it? Or am
I picking this up all wrong!!?
Should remember there’s no real world efficiency data yet and the % protected is not known .
Seems like many people might be over optimistic in what the vaccine can or can’t do but that’s what continued enforced Lockdowns do to society.
Efficacy: The benefit that a vaccine provides compared to a placebo, as measured in a clinical trial. To test a coronavirus vaccine, for instance, researchers compare how many people in the vaccinated and placebo groups get Covid-19. Effectiveness, by contrast, is the benefit that a vaccine or a drug provides out in the real world. A vaccine’s effectiveness may turn out to be lower or higher than its efficacy
@Eugene Norman: no I would rather we stopped focusing on covid in the summer. Plus I’m relaxed.
You seem to have created a narrative about me which is incorrect.
The vaccine is fine , and that’s probably the efficiency we’ll get .
It’s fine, similar to flu vaccine I’d am assuming but as this is new technology who knows it could be as high as the trail efficacy.
I think it wrong message to deliver that this vaccine Protects you.
It potentially might Protect the majority of people but the majority of people don’t get severe covid.
So we are back to the same problem, Protecting the most vunerable.
@David Jordan: do you know if the republicans who were there also tested positive? I don’t have access to that wapo article and it didn’t specify on CNN. I would be interested to find out if symptoms were mitigated. Though I imagine it would be very hard to tell from a small number of people as the virus affects everyone very differently
What is the point of this vaccine if not to prevent transmission?
I am pro vaccine and have had many, however my confidence in this one is affected by them not knowing what it does, especially after all the testing that we are told has been done!
@john doe: the point is purely to stop severe covid developing.
The immune system recognises the virus and does it’s function and doesn’t go into overdrive.
If it doesn’t stop transmission but stops illness it’s doesn’t matter much after all 97% of cases don’t need hospitalistions or ICU or worse so if 20% of the most vunerable are protected the rest of the population would not be experiencing much illness then.
One of the problems with this and all Viruses is that it looks it will continue to mutate and might be around like a yearly flu type illness.
Nobody can predict or know best , guesswork mainly.
It’s important to remember everyone should optimise their Immune System if possible and that message doesn’t get much attention in the agenda been pushed.
US and Russian officials begin talks in Saudi Arabia on resetting relations and Ukraine war
2 hrs ago
5.2k
68
Pump and dump
Argentine President Javier Milei called 'crypto-scammer' for promoting currency before crash
12 mins ago
284
2
Fatal Stabbing
Gardaí make third arrest in connection with fatal stabbing on South Anne Street as victim named
Updated
13 hrs ago
66.8k
Your Cookies. Your Choice.
Cookies help provide our news service while also enabling the advertising needed to fund this work.
We categorise cookies as Necessary, Performance (used to analyse the site performance) and Targeting (used to target advertising which helps us keep this service free).
We and our 148 partners store and access personal data, like browsing data or unique identifiers, on your device. Selecting Accept All enables tracking technologies to support the purposes shown under we and our partners process data to provide. If trackers are disabled, some content and ads you see may not be as relevant to you. You can resurface this menu to change your choices or withdraw consent at any time by clicking the Cookie Preferences link on the bottom of the webpage .Your choices will have effect within our Website. For more details, refer to our Privacy Policy.
We and our vendors process data for the following purposes:
Use precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a device. Personalised advertising and content, advertising and content measurement, audience research and services development.
Cookies Preference Centre
We process your data to deliver content or advertisements and measure the delivery of such content or advertisements to extract insights about our website. We share this information with our partners on the basis of consent. You may exercise your right to consent, based on a specific purpose below or at a partner level in the link under each purpose. Some vendors may process your data based on their legitimate interests, which does not require your consent. You cannot object to tracking technologies placed to ensure security, prevent fraud, fix errors, or deliver and present advertising and content, and precise geolocation data and active scanning of device characteristics for identification may be used to support this purpose. This exception does not apply to targeted advertising. These choices will be signaled to our vendors participating in the Transparency and Consent Framework.
Manage Consent Preferences
Necessary Cookies
Always Active
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work.
Targeting Cookies
These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.
Functional Cookies
These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then these services may not function properly.
Performance Cookies
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not be able to monitor our performance.
Store and/or access information on a device 102 partners can use this purpose
Cookies, device or similar online identifiers (e.g. login-based identifiers, randomly assigned identifiers, network based identifiers) together with other information (e.g. browser type and information, language, screen size, supported technologies etc.) can be stored or read on your device to recognise it each time it connects to an app or to a website, for one or several of the purposes presented here.
Personalised advertising and content, advertising and content measurement, audience research and services development 133 partners can use this purpose
Use limited data to select advertising 103 partners can use this purpose
Advertising presented to you on this service can be based on limited data, such as the website or app you are using, your non-precise location, your device type or which content you are (or have been) interacting with (for example, to limit the number of times an ad is presented to you).
Create profiles for personalised advertising 75 partners can use this purpose
Information about your activity on this service (such as forms you submit, content you look at) can be stored and combined with other information about you (for example, information from your previous activity on this service and other websites or apps) or similar users. This is then used to build or improve a profile about you (that might include possible interests and personal aspects). Your profile can be used (also later) to present advertising that appears more relevant based on your possible interests by this and other entities.
Use profiles to select personalised advertising 74 partners can use this purpose
Advertising presented to you on this service can be based on your advertising profiles, which can reflect your activity on this service or other websites or apps (like the forms you submit, content you look at), possible interests and personal aspects.
Create profiles to personalise content 36 partners can use this purpose
Information about your activity on this service (for instance, forms you submit, non-advertising content you look at) can be stored and combined with other information about you (such as your previous activity on this service or other websites or apps) or similar users. This is then used to build or improve a profile about you (which might for example include possible interests and personal aspects). Your profile can be used (also later) to present content that appears more relevant based on your possible interests, such as by adapting the order in which content is shown to you, so that it is even easier for you to find content that matches your interests.
Use profiles to select personalised content 32 partners can use this purpose
Content presented to you on this service can be based on your content personalisation profiles, which can reflect your activity on this or other services (for instance, the forms you submit, content you look at), possible interests and personal aspects. This can for example be used to adapt the order in which content is shown to you, so that it is even easier for you to find (non-advertising) content that matches your interests.
Measure advertising performance 124 partners can use this purpose
Information regarding which advertising is presented to you and how you interact with it can be used to determine how well an advert has worked for you or other users and whether the goals of the advertising were reached. For instance, whether you saw an ad, whether you clicked on it, whether it led you to buy a product or visit a website, etc. This is very helpful to understand the relevance of advertising campaigns.
Measure content performance 59 partners can use this purpose
Information regarding which content is presented to you and how you interact with it can be used to determine whether the (non-advertising) content e.g. reached its intended audience and matched your interests. For instance, whether you read an article, watch a video, listen to a podcast or look at a product description, how long you spent on this service and the web pages you visit etc. This is very helpful to understand the relevance of (non-advertising) content that is shown to you.
Understand audiences through statistics or combinations of data from different sources 72 partners can use this purpose
Reports can be generated based on the combination of data sets (like user profiles, statistics, market research, analytics data) regarding your interactions and those of other users with advertising or (non-advertising) content to identify common characteristics (for instance, to determine which target audiences are more receptive to an ad campaign or to certain contents).
Develop and improve services 79 partners can use this purpose
Information about your activity on this service, such as your interaction with ads or content, can be very helpful to improve products and services and to build new products and services based on user interactions, the type of audience, etc. This specific purpose does not include the development or improvement of user profiles and identifiers.
Use limited data to select content 37 partners can use this purpose
Content presented to you on this service can be based on limited data, such as the website or app you are using, your non-precise location, your device type, or which content you are (or have been) interacting with (for example, to limit the number of times a video or an article is presented to you).
Use precise geolocation data 42 partners can use this special feature
With your acceptance, your precise location (within a radius of less than 500 metres) may be used in support of the purposes explained in this notice.
Actively scan device characteristics for identification 24 partners can use this special feature
With your acceptance, certain characteristics specific to your device might be requested and used to distinguish it from other devices (such as the installed fonts or plugins, the resolution of your screen) in support of the purposes explained in this notice.
Ensure security, prevent and detect fraud, and fix errors 82 partners can use this special purpose
Always Active
Your data can be used to monitor for and prevent unusual and possibly fraudulent activity (for example, regarding advertising, ad clicks by bots), and ensure systems and processes work properly and securely. It can also be used to correct any problems you, the publisher or the advertiser may encounter in the delivery of content and ads and in your interaction with them.
Deliver and present advertising and content 92 partners can use this special purpose
Always Active
Certain information (like an IP address or device capabilities) is used to ensure the technical compatibility of the content or advertising, and to facilitate the transmission of the content or ad to your device.
Match and combine data from other data sources 65 partners can use this feature
Always Active
Information about your activity on this service may be matched and combined with other information relating to you and originating from various sources (for instance your activity on a separate online service, your use of a loyalty card in-store, or your answers to a survey), in support of the purposes explained in this notice.
Link different devices 48 partners can use this feature
Always Active
In support of the purposes explained in this notice, your device might be considered as likely linked to other devices that belong to you or your household (for instance because you are logged in to the same service on both your phone and your computer, or because you may use the same Internet connection on both devices).
Identify devices based on information transmitted automatically 81 partners can use this feature
Always Active
Your device might be distinguished from other devices based on information it automatically sends when accessing the Internet (for instance, the IP address of your Internet connection or the type of browser you are using) in support of the purposes exposed in this notice.
Save and communicate privacy choices 60 partners can use this special purpose
Always Active
The choices you make regarding the purposes and entities listed in this notice are saved and made available to those entities in the form of digital signals (such as a string of characters). This is necessary in order to enable both this service and those entities to respect such choices.
have your say